The Medicines Company’s announced its positive results concerning ALN-PCSsc at the ESC Congress 2015 on Sunday. ALN-PCSsc is a drug that is designed to treat hypercholesterolemia, commonly called high cholesterol, by stopping production of PCSK9, which regulates the LDL-C, in the liver.
The results from The Medicines Company’s recent Phase 1 clinical trials found that ALN-PCSsc has the ability to reduce LDL-C by up to 83%. This was achieved with a dose of 300 mg and the study found that the drug could hold cholesterol levels low for at least 140 days.
With the positive results from the Phase 1 clinical trials, The Medicines Company’s is now planning to start Phase 2 and Phase 3 trials. The Phase 2 trials are expected to start by the end of the year and Phase 3 trials are currently set to start before 2017’s end.
MDCO shares were up 18% as of Monday afternoon.